WASHINGTON — The United States and United Kingdom announced a high-level agreement Monday under which the U.K. is expected to pay more for medicines.
In exchange for agreeing to increase payments going forward, the U.K. will be spared from pharmaceutical tariffs being considered by the Trump administration.
The announcement represents a crucial element of President Trump’s agenda to lower U.S. drug prices and to get other rich nations, which generally pay far less for medicines than the U.S., to pay more. The Trump administration has struck confidential deals with a handful of drugmakers to lower their prices in some U.S. plans, particularly Medicaid.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
